The current opioid epidemic in the US has its historical roots in the movement during the 1990s to address undertreated chronic pain. In response, opioid-producing pharmaceutical companies engaged in aggressive marketing and prescribers overcorrected, relying on powerful opioid analgesics to treat acute and minor pain in addition to chronic and severe pain. Subsequently, the widespread use of opioid analgesic agents created demand for long-term and non-medical use of prescription and illicit opioids.
1,2 To address the growing opioid epidemic, policy makers have focused largely on controlling the prescription and use of opioid analgesics through the implementation of supply-side drug policies. These include prescription drug monitoring programs (PDMPs), pain clinic laws, and prescription limit laws to reduce inappropriate prescribing behavior. In tandem, policy measures to reduce harms and barriers associated with treating and reporting drug overdose, including naloxone access laws and Good Samaritan laws, have been introduced.